Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT06346392

PHASE3

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Sponsor: AstraZeneca

View on ClinicalTrials.gov

Summary

The purpose of this study is to measure the efficacy and safety of AZD0901 compared to Investigator's choice of therapy as 2L+ treatment for participants with advanced or metastatic gastric or GEJ adenocarcinoma expressing CLDN18.2.

Official title: A Phase III Multi-center, Open-label, Sponsor-blinded, Randomized Study of AZD0901 Monotherapy Compared With Investigator's Choice of Therapy in Second- or Later-Line Adult Participants With Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 (CLARITY Gastric 01)

Key Details

Gender

All

Age Range

18 Years - 130 Years

Study Type

INTERVENTIONAL

Enrollment

594

Start Date

2024-03-04

Completion Date

2026-10-14

Last Updated

2026-10-15

Healthy Volunteers

Conditions

Gastric Cancer Gastroesophageal Junction Cancer

Interventions

DRUG

AZD0901

Participants in the AZD0901 arm 1 will receive dose level 1 AZD0901 IV

DRUG

AZD0901

Participants in the AZD0901 arm 2 will receive dose level 2 AZD0901 IV (Enrolment was closed)

DRUG

Ramucirumab+ paclitaxel

Ramucirumab 8 mg/kg IV on Days 1 and 15 and paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W

DRUG

Paclitaxel

Paclitaxel 80 mg/m2 IV on Days 1, 8, and 15, Q4W (for participants with contraindication to ramucirumab only)

DRUG

Docetaxel

Docetaxel 75-100 mg/m2 IV on Day 1, Q3W (for participants with contraindication to ramucirumab only)

DRUG

Irinotecan

Irinotecan 150-180 mg/m2 IV on Days 1 and 15, Q4W

DRUG

TAS-102

TAS-102 35 mg/m2 up to a maximum of 80 mg orally twice a day on Days 1 to 5 and Days 8 to 12, Q4W (except China)

DRUG

Apatinib

Apatinib 500-850 mg at Investigator's discretion based on participant's condition and tolerability, orally once daily, Q4W (China only)

Inclusion Criteria: 1. Capable of giving signed informed consent prior to any study procedure. 2. Participant must be at least 18 years or the legal age of consent in the jurisdiction in which the study is taking place at the time of signing the ICF. 3. Histologically confirmed unresectable, locally advanced or metastatic adenocarcinoma of gastric, GEJ, or distal esophagus (distal third of the esophagus) and the following requirement: (a) Participants with positive CLDN18.2 expression from archival tumor collected within past 24 months or from a fresh biopsy. 4. Disease progression on or after at least one prior line of treatment (LoT) for advanced or metastatic disease, which included a fluoropyrimidine and a platinum, for advanced or metastatic disease. 5. Must have at least one measurable or evaluable lesion assessed by the Investigator based on RECIST 1.1. 6. ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 7. Predicted life expectancy of ≥ 12 weeks. 8. Adequate organ and bone marrow function 9. Body weight of ≥ 35 kg. 10. Sex and Contraceptive Requirements Exclusion Criteria: 1. Participants with known HER2 positive status as defined as IHC 3+ or IHC 2+/ISH + (Cases with HER2: CEP17 ratio ≥ 2 or an average HER2 copy number ≥ 6.0 signals/cell are considered positive by ISH). Participants must undergo local (or have had) HER2 testing by IHC/ISH, and the most recent result of HER2 status will be used to determine the eligibility. 2. Participant has significant or unstable gastric bleeding and/or untreated gastric ulcers. 3. CNS metastases or CNS pathology including: epilepsy, seizures or aphasia within 3 months prior to consent, severe brain injury, dementia, Parkinson's disease, neurodegenerative diseases, cerebellar disease, severe uncontrolled mental illness, psychosis, CNS involvement of autoimmune diseases. 4. Participant has known clinically significant corneal disease (eg, active keratitis or corneal ulcerations). 5. Persistent toxicities (CTCAE Grade ≥ 2) caused by previous anticancer therapy, excluding alopecia. Participants with irreversible toxicity that is not reasonably expected to be exacerbated by study intervention may be included (eg, hearing loss). 6. Prior exposure to any ADC with MMAE payload or any CLDN18.2 targeting treatment other than naked monoclonal antibody (eg, CLDN18.2 targeting CAR-T cell therapy, multi-specific antibody including targeting CLDN18.2, etc). 7. History of thromboembolic events: 1. Participants with venous thromboembolism within the past 6 months prior to randomization: participants with venous port or catheter thrombosis or superficial venous thrombus that do not require treatment or are stable on treatment with anticoagulants are excepted 2. History of arterial thromboembolism within the past 12 months prior to randomization 8. As judged by the Investigator, any evidence of diseases which in the Investigator's opinion, makes it undesirable for the participant to participate in the study or that would jeopardize compliance with the protocol.

Locations (158)

Research Site

Mobile, Alabama, United States

Research Site

Tucson, Arizona, United States

Research Site

Duarte, California, United States

Research Site

Irvine, California, United States

Research Site

Los Angeles, California, United States

Research Site

Los Angeles, California, United States

Research Site

Newport Beach, California, United States

Research Site

Washington D.C., District of Columbia, United States

Research Site

Hollywood, Florida, United States

Research Site

Orlando, Florida, United States

Research Site

Marietta, Georgia, United States

Research Site

Boise, Idaho, United States

Research Site

Lexington, Kentucky, United States

Research Site

Boston, Massachusetts, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Ann Arbor, Michigan, United States

Research Site

Kansas City, Missouri, United States

Research Site

Mineola, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

New York, New York, United States

Research Site

Philadelphia, Pennsylvania, United States

Research Site

York, Pennsylvania, United States

Research Site

Charlottesville, Virginia, United States

Research Site

Fredericksburg, Virginia, United States

Research Site

Olympia, Washington, United States

Research Site

Ribeirão Preto, Brazil

Research Site

São Paulo, Brazil

Research Site

Vitória, Brazil

Research Site

Barrie, Ontario, Canada

Research Site

London, Ontario, Canada

Research Site

North York, Ontario, Canada

Research Site

Ottawa, Ontario, Canada

Research Site

Toronto, Ontario, Canada

Research Site

Montreal, Quebec, Canada

Research Site

Beijing, China

Research Site

Changchun, China

Research Site

Chengdu, China

Research Site

Chengdu, China

Research Site

Fuzhou, China

Research Site

Fuzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Guangzhou, China

Research Site

Hangzhou, China

Research Site

Hangzhou, China

Research Site

Harbin, China

Research Site

Hefei, China

Research Site

Hefei, China

Research Site

Hefei, China

Research Site

Jinan, China

Research Site

Jining, China

Research Site

Lanzhou, China

Research Site

Lishui, China

Research Site

Nanjing, China

Research Site

Qingdao, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shanghai, China

Research Site

Shenyang, China

Research Site

Shijiazhuang, China

Research Site

Suzhou, China

Research Site

Tianjin, China

Research Site

Ürümqi, China

Research Site

Wuhan, China

Research Site

Wuhan, China

Research Site

Xi'an, China

Research Site

Yinchuan, China

Research Site

Zhengzhou, China

Research Site

Besançon, France

Research Site

Brest, France

Research Site

Lille, France

Research Site

Lyon, France

Research Site

Nantes, France

Research Site

Berlin, Germany

Research Site

Berlin, Germany

Research Site

Frankfurt, Germany

Research Site

Göttingen, Germany

Research Site

Hamburg, Germany

Research Site

Heidelberg, Germany

Research Site

Heilbronn, Germany

Research Site

Leipzig, Germany

Research Site

Marburg, Germany

Research Site

Moers, Germany

Research Site

München, Germany

Research Site

Hong Kong, Hong Kong

Research Site

Hong Kong, Hong Kong

Research Site

Ahmedabad, India

Research Site

Hyderabad, India

Research Site

Mumbai, India

Research Site

New Delhi, India

Research Site

Florence, Italy

Research Site

Milan, Italy

Research Site

Milan, Italy

Research Site

Naples, Italy

Research Site

Padova, Italy

Research Site

Pisa, Italy

Research Site

Vicenza, Italy

Research Site

Fukuoka, Japan

And 58 more locations on ClinicalTrials.gov

Clinical Research Directory

AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2

Summary

Key Details

Conditions

Interventions

Eligibility Criteria

Locations (158)